Sucrose lysis test

Sucrose lysis test

Sucrose Lysis Test is a diagnostic laboratory test used primarily to detect the presence of Paroxysmal Nocturnal Hemoglobinuria (PNH), a rare, acquired, potentially life-threatening disease of the blood characterized by the destruction of red blood cells (hemolysis), blood clots (thrombosis), and impaired bone marrow function (leading to insufficient production of blood cells). The test is based on the principle that red blood cells (RBCs) from individuals with PNH are more sensitive to lysis by sucrose in an acidified serum environment due to the deficiency of certain surface proteins that normally protect the cell membrane from complement-mediated lysis.

Procedure

The Sucrose Lysis Test involves mixing the patient's blood with a low ionic strength solution containing sucrose. The test exploits the vulnerability of PNH red blood cells to lysis in hypotonic solutions, due to their increased sensitivity to the complement system, a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear pathogens. In a normal individual, RBCs are relatively resistant to lysis under these conditions because of the presence of CD55 and CD59, proteins that inhibit complement activation on the cell surface. However, in PNH patients, these proteins are deficient, leading to increased hemolysis in the test solution.

Interpretation

A positive Sucrose Lysis Test indicates increased red blood cell destruction in the sucrose solution, suggestive of PNH. However, it is important to note that a positive result is not definitive for PNH and must be confirmed with more specific tests, such as flow cytometry to detect the absence of CD55 and CD59 on the surface of red blood cells. Conversely, a negative test result usually indicates the absence of PNH but does not rule out other causes of hemolytic anemia.

Limitations

The Sucrose Lysis Test, while useful, has several limitations. It is not highly specific for PNH and can give false positive results in other conditions where red blood cells are more susceptible to complement-mediated lysis. Additionally, the test's sensitivity is not optimal; mild cases of PNH may not be detected. Due to these limitations, the test is often used as a screening tool rather than a definitive diagnostic test.

Conclusion

The Sucrose Lysis Test plays a role in the initial screening for PNH, guiding further diagnostic testing. Despite its limitations, it remains a useful tool in the diagnostic workup of patients with suspected hemolytic anemias, particularly when PNH is a consideration. However, definitive diagnosis requires confirmation by more specific methods, such as flow cytometry.